Stroke D020521

Description

A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)   MeSH

Subtype Terms (2)

Brain Infarction
177 drugs (81 approved, 96 experimental)

Stroke, Lacunar
4 approved drugs


Phase 4 Indicated Drugs (93)

Key: D020521 (82) Subtype (11)

Phase 3 Indicated Drugs (102)

Key: D020521 (98) Subtype (4)

Phase 2 Indicated Drugs (122)

Key: D020521 (113) Subtype (9)


Organization Involved with Phase 4 Indications (115)

Key: D020521 (107) Subtype (8)

Organization Involved with Phase 3 Indications (138)

Key: D020521 (133) Subtype (5)

Organization Involved with Phase 2 Indications (132)

Key: D020521 (120) Subtype (12)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.